Menopause-related risks and hormone therapy in diabetic women;Risques liés à la ménopause et traitement hormonal de la femme diabétique

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 586-589

  Gaspard, U ^a   Van Den Brule F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk factors; Diabetes mellitus; Hormone replacement therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG INDICATION; HEMOSTASIS; HORMONAL THERAPY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MENOPAUSE; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; RISK FACTORS;

EID: 21744449771     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Barrett-Connor E, Bush TL.- Estrogen and coronary heart disease in women. JAMA, 1991, 265, 1861-1867.
2. Scheen AJ, Luyckx FH.- Le syndrome métabolique: définitions et données épidémiologiques. Rev Méd Liège, 2003, 58, 479-484.
3. Walton C, Godsland IF, Proudler AJ et al.- The effects of the menopause on insulin sensitivity secretion and elimination in non-obese, healthy women. Eur J Clin Invest, 1993, 23, 466-473.
4. Gaspard UJ, Gottal JM, van den Brûle FA.- Postmenopausal changes in lipid and glucose metabolism: a review of their main aspects. Maturitas, 1995, 21, 171-178.
5. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: Consensus opinion of the North American Menopause Society. Menopause, 2000, 7, 87-95.
6. Beral V, Reeves G, Banks E.- Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. Br J Obstet Gynaecol, 2005, 112, 1-4.
7. Godsland IF.- Effect on carbohydrate metabolism In: "Estrogens and progestogens in clinical practice", Fraser IS, Janssen RPS, Lobo RA, Whitehead MI, Churchill Livingstone, London, 1998 pp 773-785.
8. Gaspard UJ, Wéry OJ, Scheen AJ et al.- Long term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric, 1999, 2, 93-100.
9. Sargeant LA, Wareham NH, Khaw KT.- Hormone replacement Therapy and glucose tolerance in EPIC-Norfolk: a population-based study. Diab Metab Res Rev. 2000, 16, 20-25.
10. Godsland IF.- Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations. Analysis of studies published from 1974-2000. Fertil Steril, 2001, 75, 898-915.
11. Ferrara A, Karter AJ, Ackerson LM et al.- Hormone Replacement Therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes care, 2001, 24, 1144-1150.
12. Perera M, Sattar N, Petrie JR et al.- The effects of transdermal estradiol, in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab, 2001, 86, 1140-1143.
13. Manwaring P, Morfis L, Diamond T et al.- The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas, 2000, 34, 239-247.
14. Rossi R, Origliani G, Modena MG.- Transdermal 17 beta oestradiol and risk of developing type 2 diabetes in a population of healthy, non obese postmenopausal women. Diabetes Care, 2004, 27, 645-649.
15. Margolis KL, Bonds DE, Rodabough RJ et al.- Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia, 2004, 47, 1175-1187.
16. Kanaya AM, Herrington D, Vittinghoff E et al.- Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2003, 138, 109.
17. Lindheim SR, Presser SC, Ditkoff EC et al.- A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril, 1993, 60, 664-667.
18. Oger E, Alhenc-Gelas M, Lacut K et al.- Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. Arterioscler Throtnb Vasc Biol, 2003, 23, 1671-1676.
19. Scarabin PY, Oger E, Plu-Bureau G et al.- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolic risk. Lancet, 2003, 362, 428-432.
20. Gaspard U, van den Brûle Fr.- Angeliq: nouvelle hormonothérapie de la ménopause comportant des propriétés antialdostérone et antiandrogéniques. Rev Med Liège, 2004, 59, 162-166.